Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study

Robert Klamroth, Karin Kurnik, Swee Wenning, Carmen Escuriola-Ettingshausen, Stephan Regensburger, Leilei Tang, Joan Gu, Randy Guerra, Johannes Oldenburg

Blood (2021) 138 (Supplement 1): 3187.

https://doi.org/10.1182/blood-2021-146162

Published: 2021

Journal Articles

Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

Manuel Carcao, MD, Maria L. Avila, MD, Victor S. Blanchette, MD FRCP, Elena Santagostino, MD PhD, Carmen Escuriola-Ettingshausen, MD PhD, Cindy A. Leissinger, MD, Thierry Lambert, Louis M. Aledort, MD

Blood (2015) 126 (23): 3535.

https://doi.org/10.1182/blood.V126.23.3535.3535

Published: 2015

Journal Articles

Factor VIII gene ( F8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

Corien L. Eckhardt, Alice S. van Velzen, Marjolein Peters, Jan Astermark, Paul P. Brons, Giancarlo Castaman, Marjon H. Cnossen, Natasja Dors, Carmen Escuriola-Ettingshausen, Karly Hamulyak, Daniel P. Hart, Charles R. M. Hay, Saturnino Haya, Waander L. van Heerde, Cedric Hermans, Margareta Holmström, Victor Jimenez-Yuste, Russell D. Keenan, Robert Klamroth, Britta A. P. Laros-van Gorkom, Frank W. G. Leebeek, Ri Liesner, Anne Mäkipernaa, Christoph Male, Evelien Mauser-Bunschoten, Maria G. Mazzucconi, Simon McRae, Karina Meijer, Michael Mitchell, Massimo Morfini, Marten Nijziel, Johannes Oldenburg, Kathelijne Peerlinck, Pia Petrini, Helena Platokouki, Sylvia E. Reitter-Pfoertner, Elena Santagostino, Piercarla Schinco, Frans J. Smiers, Berthold Siegmund, Annarita Tagliaferri, Thynn T. Yee, Pieter Willem Kamphuisen, Johanna G. van der Bom, Karin Fijnvandraat

Blood (2013) 122 (11): 1954–1962.

https://doi.org/10.1182/blood-2013-02-483263

Published: 2013

Includes: Supplemental data

Journal Articles

Influence of Factor V G1691A or Prothrombin G20210A Mutation On Inhibitor Development in Patients with Severe Hemophilia A - an Israeli-German Database Study.

Gili Kenet, MD, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, MD, Sven Gutsche, MD, Susan Halimeh, MD, Verena Janssen, MD, Karin Kurnik, MD, Ulrike Nowak-Gottl, MD

Blood (2012) 120 (21): 2234.

https://doi.org/10.1182/blood.V120.21.2234.2234

Published: 2012

Journal Articles

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate ® in the Observational ObsITI Study,

Carmen Escuriola-Ettingshausen, MD, Vladimir Vdovin, MD, Nadezhda Zozulya, MD, PhD, Olga Plyushch, Prof, Wolfhart Kreuz, MD, Bruce A. Schwartz, PhD

Blood (2011) 118 (21): 3310.

https://doi.org/10.1182/blood.V118.21.3310.3310

Published: 2011

Journal Articles

A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study

Susanne Holzhauer, MD, Christoph Bidlingmaier, MD, Carmen Escuriola Ettingshausen, MD, Susan Halimeh, MD, Alfonso Iorio, MD, Gili Kenet, MD, Brigitte Pautard, MD, Ulrike Nowak-Gottl, MD

Blood (2010) 116 (21): 710.

https://doi.org/10.1182/blood.V116.21.710.710

Published: 2010

Journal Articles

Impact of Treatment Intensity and Factor VIII Products On the Development On High Titre Inhibitors in Children with Severe Hemophilia A: Results of a Non-Concurrent Cohort Study.

Karin Kurnik, MD, Susan Halimeh, MD, Daniela Manner, MD, Susanne Holzhauer, MD, Carmen Escuriola Ettingshausen, MD, Rosemarie Schobess, MD, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 1303.

https://doi.org/10.1182/blood.V114.22.1303.1303

Published: 2009

Journal Articles

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Alfonso Iorio, MD, Susan Halimeh, MD, Christoph Bidlingmaier, MD, Leonardo R. Brandao, MD, Carmen Escuriola-Ettingshausen, MD, Neil A Goldenberg, MD, PhD, Alessandro Gringeri, MD, MSc, Susanne Holzhauer, MD, Gili Kenet, MD, PhD, Ralf Knoefler, MD, Wolfhart Kreuz, MD, Karin Kurnik, MD, Daniela Manner, MD, Emanuela Marchesini, MD, Maura Marcucci, MD, Elena Santagostino, MD, PhD, Guy Young, MD, Pier Mannuccio Mannucci, MD, Ulrike Nowak-Gottl, MD

Blood (2009) 114 (22): 3154.

https://doi.org/10.1182/blood.V114.22.3154.3154

Published: 2009

Journal Articles

Effects of “Primary Prophylaxis” and “On-Demand” Therapy on the Clinical Expression of Severe Hemophilia A in Children - Results of a Multicenter Study.

Rosemarie Schobess, Karin Kurnik, Wolfhart Kreuz, Frauke Friedrichs, Anne Krumpel, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, Ulrike Nowak-Gottl

Blood (2007) 110 (11): 3146.

https://doi.org/10.1182/blood.V110.11.3146.3146

Published: 2007

Journal Articles

Immune Tolerance Induction (ITI) in Hemophilia A and Inhibitors using VWF Containing Factor VIII Concentrates.

Wolfhart Kreuz, MD, Carmen Escuriola Ettingshausen, MD, Guenter K.H. Auerswald, MD, Hans Herrmann Brackmann, MD, Thomas Klingebiel, MD

Blood (2004) 104 (11): 3092.

https://doi.org/10.1182/blood.V104.11.3092.3092

Published: 2004

Journal Articles

The Role of Age at First Exposure and Therapy Regimen on the Development of Neutralizing FVIII Antibodies in Hemophilia A.

Carmen Escuriola Ettingshausen, MD, Alexandra Zyschka, Inmaculada Martinez Saguer, MD, Christine Heller, MD, Thomas Klingebiel, MD, Wolfhart Kreuz, MD

Blood (2004) 104 (11): 3082.

https://doi.org/10.1182/blood.V104.11.3082.3082

Published: 2004

Journal Articles

Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease

Carmen Escuriola Ettingshausen, Karin Kurnik, Rosemarie Schobess, Wolfart D. Kreuz, Susan Halimeh, Hartmut Pollman, Ulrike Nowak-Göttl

Blood (2002) 99 (4): 1499.

https://doi.org/10.1182/blood.V99.4.1499

Published: 2002

NARROW

Pharmacokinetic-Guided Prophylaxis with Rurioctocog Alfa Pegol Improves Bleeding Rates over Standard Prophylaxis: Real-World Observational Data from the Ahead German Study

Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

Factor VIII gene ( F8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

Influence of Factor V G1691A or Prothrombin G20210A Mutation On Inhibitor Development in Patients with Severe Hemophilia A - an Israeli-German Database Study.

ITI with a VWF-Stabilised FVIII Concentrate in Haemophilia A Patients with Inhibitors and a Poor Prognosis for ITI Success: Progress Report on octanate ® in the Observational ObsITI Study,

A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study

Impact of Treatment Intensity and Factor VIII Products On the Development On High Titre Inhibitors in Children with Severe Hemophilia A: Results of a Non-Concurrent Cohort Study.

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Effects of “Primary Prophylaxis” and “On-Demand” Therapy on the Clinical Expression of Severe Hemophilia A in Children - Results of a Multicenter Study.

Immune Tolerance Induction (ITI) in Hemophilia A and Inhibitors using VWF Containing Factor VIII Concentrates.

The Role of Age at First Exposure and Therapy Regimen on the Development of Neutralizing FVIII Antibodies in Hemophilia A.

Catheter-related thrombosis in children with hemophilia A: evidence of a multifactorial disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only